CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

(2013) Florian Klein et al.   CELL

Modeling Virus- and Antibody-Specific Factors to Predict Human Immunodeficiency Virus Neutralization Efficiency

(2013) Hillel Haim et al.   Cell Host & Microbe

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

(2013) Hua-Xin Liao et al.   IMMUNITY

Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design

(2013) L.-H. Ping et al.   JOURNAL OF VIROLOGY

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies

(2013) Mohammed N Amin et al.   Nature Chemical Biology

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120

(2013) Leopold Kong et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Stabilizing Exposure of Conserved Epitopes by Structure Guided Insertion of Disulfide Bond in HIV-1 Envelope Glycoprotein

(2013) Aemro Kassa et al.   PLoS One

Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer

(2013) Y. Mao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

(2013) J. Jardine et al.   SCIENCE

Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization

(2013) Judith M. LaLonde et al.   ACS Medicinal Chemistry Letters

Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes

(2013) Constantinos Kurt Wibmer et al.   PLoS Pathogens

The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

(2012) Nicos Karasavvas et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A Blueprint for HIV Vaccine Discovery

(2012) Dennis R. Burton et al.   Cell Host & Microbe

Optimization of CD4/gp120 Inhibitors by Thermodynamic-Guided Alanine-Scanning Mutagenesis

(2012) Yingyun Liu et al.   Chemical Biology & Drug Design

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

(2012) D. C. Montefiori et al.   JOURNAL OF INFECTIOUS DISEASES

Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors

(2012) Judith M. LaLonde et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mining the mechanisms of an HIV vaccine

(2012)   NATURE MEDICINE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum

(2012) James Friedman et al.   PLoS One

Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops

(2012) Y. D. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection

(2011) E. S. Gray et al.   JOURNAL OF VIROLOGY

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

(2011) Jason S. McLellan et al.   NATURE

Broad neutralization coverage of HIV by multiple highly potent antibodies

(2011) Laura M. Walker et al.   NATURE

Moving ahead an HIV vaccine: Use both arms to beat HIV

(2011) Bruce D Walker et al.   NATURE MEDICINE

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

(2011) D. R. Burton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

(2011) R. Pejchal et al.   SCIENCE

Contribution of Intrinsic Reactivity of the HIV-1 Envelope Glycoproteins to CD4-Independent Infection and Global Inhibitor Sensitivity

(2011) Hillel Haim et al.   PLoS Pathogens

Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening

(2010) Judith M. LaLonde et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged

(2010) Katie J. Doores et al.   JOURNAL OF VIROLOGY

Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Epitopes through Binding of CD4 Mimetic Compounds

(2010) K. Yoshimura et al.   JOURNAL OF VIROLOGY

Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing

(2010) Will Fischer et al.   PLoS One

Toward an Antibody-Based HIV-1 Vaccine

(2009) James A. Hoxie   Annual Review of Medicine

Identification of a Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Variant Resistant to Cold Inactivation

(2009) A. Kassa et al.   JOURNAL OF VIROLOGY

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

(2009) Leonidas Stamatatos et al.   NATURE MEDICINE

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

(2009) L. Chen et al.   SCIENCE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection

(2009) Penny L. Moore et al.   PLoS Pathogens

Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site

(2009) Barna Dey et al.   PLoS Pathogens

Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated State

(2009) Hillel Haim et al.   PLoS Pathogens

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

(2009) Ann J. Hessell et al.   PLoS Pathogens

Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma

(2008) K. L. Davis et al.   JOURNAL OF VIROLOGY

Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection

(2008) D. N. Sather et al.   JOURNAL OF VIROLOGY

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

(2008) B. F. Keele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120

(2008) Navid Madani et al.   STRUCTURE

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity

(2008) Ralph Pantophlet et al.   VIROLOGY